Allergan’s acquisition of Corneal and other, smaller businesses in France created the opportunity to join forces and introduce a new game-changing hyaluronic acid filler to clinics. Initially, they were focusing on the EMEA region only.
The market was being dominated by one brand, Restylane from Q-Med. Our task was to first get under the skin of this sector and then turn it upside down by launching a new brand that could seriously challenge the runaway market leader.